angiogenesis

血管新生

　

WordNet

1. the formation of new blood vessels
2. the organic process whereby body tissue becomes vascular and develops capillaries (同)vascularisation
3. an operation to repair a damaged blood vessel or unblock a coronary artery

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/12/11 09:46:55」(JST)

wiki en

[Wiki en表示]

Not to be confused with vasculogenesis.

Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels. This is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in the developing embryo form through vasculogenesis, after which angiogenesis is responsible for most, if not all, blood vessel growth during development and in disease.

Angiogenesis is a normal and vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, it is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. The essential role of angiogenesis in tumor growth was first proposed in 1971 by Judah Folkman, who described tumors as "hot and bloody."

Types

Sprouting angiogenesis

Sprouting angiogenesis was the first identified form of angiogenesis. It occurs in several well-characterized stages. First, biological signals known as angiogenic growth factors activate receptors on endothelial cells present in pre-existing blood vessels. Second, the activated endothelial cells begin to release enzymes called proteases that degrade the basement membrane to allow endothelial cells to escape from the original (parent) vessel walls. The endothelial cells then proliferate into the surrounding matrix and form solid sprouts connecting neighboring vessels. As sprouts extend toward the source of the angiogenic stimulus, endothelial cells migrate in tandem, using adhesion molecules called integrins. These sprouts then form loops to become a full-fledged vessel lumen as cells migrate to the site of angiogenesis. Sprouting occurs at a rate of several millimeters per day, and enables new vessels to grow across gaps in the vasculature. It is markedly different from splitting angiogenesis because it forms entirely new vessels as opposed to splitting existing vessels.

Intussusceptive angiogenesis

Main article: Intussusception (blood vessel growth)

By Intussusception, also known as splitting angiogenesis, a new blood vessel is created by splitting of an existing blood vessel in two.

Intussusception was first observed in neonatal rats. In this type of vessel formation, the capillary wall extends into the lumen to split a single vessel in two. There are four phases of intussusceptive angiogenesis. First, the two opposing capillary walls establish a zone of contact. Second, the endothelial cell junctions are reorganized and the vessel bilayer is perforated to allow growth factors and cells to penetrate into the lumen. Third, a core is formed between the 2 new vessels at the zone of contact that is filled with pericytes and myofibroblasts. These cells begin laying collagen fibers into the core to provide an extracellular matrix for growth of the vessel lumen. Finally, the core is fleshed out with no alterations to the basic structure. Intussusception is important because it is a reorganization of existing cells. It allows a vast increase in the number of capillaries without a corresponding increase in the number of endothelial cells. This is especially important in embryonic development as there are not enough resources to create a rich microvasculature with new cells every time a new vessel develops.

Physiology

Mechanical stimulation

Mechanical stimulation of angiogenesis is not well characterized. There is a significant amount of controversy with regard to shear stress acting on capillaries to cause angiogenesis, although current knowledge suggests that increased muscle contractions may increase angiogenesis. This may be due to an increase in the production of nitric oxide during exercise. Nitric oxide results in vasodilation of blood vessels.

Chemical stimulation

Chemical stimulation of angiogenesis is performed by various angiogenic proteins, including several growth factors.

Overview

Stimulator	Mechanism
FGF	Promotes proliferation & differentiation of endothelial cells, smooth muscle cells, and fibroblasts
VEGF	Affects permeability
VEGFR and NRP-1	Integrate survival signals
Ang1 and Ang2	Stabilize vessels
PDGF (BB-homodimer) and PDGFR	recruit smooth muscle cells
TGF-β, endoglin and TGF-β receptors	↑extracellular matrix production
MCP-1
Histamine
Integrins αVβ3, αVβ5 (?) and α5β1	Bind matrix macromolecules and proteinases
VE-cadherin and CD31	endothelial junctional molecules
ephrin	Determine formation of arteries or veins
plasminogen activators	remodels extracellular matrix, releases and activates growth factors
plasminogen activator inhibitor-1	stabilizes nearby vessels
eNOS and COX-2
AC133	regulates angioblast differentiation
ID1/ID3	Regulates endothelial transdifferentiation

FGF

Further information: Fibroblast growth factor

The fibroblast growth factor (FGF) family with its prototype members FGF-1 (acidic FGF) and FGF-2 (basic FGF) consists to date of at least 22 known members. Most are single-chain peptides of 16-18 kDa and display high affinity to heparin and heparan sulfate. In general, FGFs stimulate a variety of cellular functions by binding to cell surface FGF-receptors in the presence of heparin proteoglycans. The FGF-receptor family is composed of seven members, and all the receptor proteins are single-chain receptor tyrosine kinases that become activated through autophosphorylation induced by a mechanism of FGF-mediated receptor dimerization. Receptor activation gives rise to a signal transduction cascade that leads to gene activation and diverse biological responses, including cell differentiation, proliferation, and matrix dissolution, thus initiating a process of mitogenic activity critical for the growth of endothelial cells, fibroblasts, and smooth muscle cells. FGF-1, unique among all 22 members of the FGF family, can bind to all seven FGF-receptor subtypes, making it the broadest-acting member of the FGF family, and a potent mitogen for the diverse cell types needed to mount an angiogenic response in damaged (hypoxic) tissues, where upregulation of FGF-receptors occurs. FGF-1 stimulates the proliferation and differentiation of all cell types necessary for building an arterial vessel, including endothelial cells and smooth muscle cells; this fact distinguishes FGF-1 from other pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF), which primarily drives the formation of new capillaries.

Until 2007, three human clinical trials have been successfully completed with FGF-1, in which the angiogenic protein was injected directly into the damaged heart muscle. Also, one additional human FGF-1 trial has been completed to promote wound healing in diabetics with chronic wounds.

Besides FGF-1, one of the most important functions of fibroblast growth factor-2 (FGF-2 or bFGF) is the promotion of endothelial cell proliferation and the physical organization of endothelial cells into tube-like structures, thus promoting angiogenesis. FGF-2 is a more potent angiogenic factor than VEGF or PDGF (platelet-derived growth factor); however, it is less potent than FGF-1. As well as stimulating blood vessel growth, aFGF (FGF-1) and bFGF (FGF-2) are important players in wound healing. They stimulate the proliferation of fibroblasts and endothelial cells that give rise to angiogenesis and developing granulation tissue; both increase blood supply and fill up a wound space/cavity early in the wound-healing process.

VEGF

Vascular endothelial growth factor (VEGF) has been demonstrated to be a major contributor to angiogenesis, increasing the number of capillaries in a given network. Initial in vitro studies demonstrated bovine capillary endothelial cells will proliferate and show signs of tube structures upon stimulation by VEGF and bFGF, although the results were more pronounced with VEGF. Upregulation of VEGF is a major component of the physiological response to exercise and its role in angiogenesis is suspected to be a possible treatment in vascular injuries. In vitro studies clearly demonstrate that VEGF is a potent stimulator of angiogenesis because, in the presence of this growth factor, plated endothelial cells will proliferate and migrate, eventually forming tube structures resembling capillaries. VEGF causes a massive signaling cascade in endothelial cells. Binding to VEGF receptor-2 (VEGFR-2) starts a tyrosine kinase signaling cascade that stimulates the production of factors that variously stimulate vessel permeability (eNOS, producing NO), proliferation/survival (bFGF), migration (ICAMs/VCAMs/MMPs) and finally differentiation into mature blood vessels. Mechanically, VEGF is upregulated with muscle contractions as a result of increased blood flow to affected areas. The increased flow also causes a large increase in the mRNA production of VEGF receptors 1 and 2. The increase in receptor production means muscle contractions could cause upregulation of the signaling cascade relating to angiogenesis. As part of the angiogenic signaling cascade, NO is widely considered to be a major contributor to the angiogenic response because inhibition of NO significantly reduces the effects of angiogenic growth factors. However, inhibition of NO during exercise does not inhibit angiogenesis, indicating there are other factors involved in the angiogenic response.

Angiopoietins

The angiopoietins, Ang1 and Ang2, are required for the formation of mature blood vessels, as demonstrated by mouse knock out studies. Ang1 and Ang2 are protein growth factors which act by binding their receptors, Tie-1 and Tie-2; while this is somewhat controversial, it seems that cell signals are transmitted mostly by Tie-2; though some papers show physiologic signaling via Tie-1 as well. These receptors are tyrosine kinases. Thus, they can initiate cell signaling when ligand binding causes a dimerization that initiates phosphorylation on key tyrosines.

MMP

Another major contributor to angiogenesis is matrix metalloproteinase (MMP). MMPs help degrade the proteins that keep the vessel walls solid. This proteolysis allows the endothelial cells to escape into the interstitial matrix as seen in sprouting angiogenesis. Inhibition of MMPs prevents the formation of new capillaries. These enzymes are highly regulated during the vessel formation process because destruction of the extracellular matrix would decrease the integrity of the microvasculature.

DII4

Delta-like ligand 4 (DII4) is a protein with a negative regulatory effect on angiogenesis. Dll4 is a transmembrane ligand, for the notch family of receptors.

Chemical inhibition

Main article: Angiogenesis inhibitor

Angiogenesis inhibitor can be endogenous or come from outside as drug or a dietary component.

Application in medicine

Angiogenesis as a therapeutic target

Angiogenesis may be a target for combating diseases characterized by either poor vascularisation or abnormal vasculature. Application of specific compounds that may inhibit or induce the creation of new blood vessels in the body may help combat such diseases. The presence of blood vessels where there should be none may affect the mechanical properties of a tissue, increasing the likelihood of failure. The absence of blood vessels in a repairing or otherwise metabolically active tissue may inhibit repair or other essential functions. Several diseases, such as ischemic chronic wounds, are the result of failure or insufficient blood vessel formation and may be treated by a local expansion of blood vessels, thus bringing new nutrients to the site, facilitating repair. Other diseases, such as age-related macular degeneration, may be created by a local expansion of blood vessels, interfering with normal physiological processes.

The modern clinical application of the principle of angiogenesis can be divided into two main areas: anti-angiogenic therapies, which angiogenic research began with, and pro-angiogenic therapies. Whereas anti-angiogenic therapies are being employed to fight cancer and malignancies, which require an abundance of oxygen and nutrients to proliferate, pro-angiogenic therapies are being explored as options to treat cardiovascular diseases, the number one cause of death in the Western world. One of the first applications of pro-angiogenic methods in humans was a German trial using fibroblast growth factor 1 (FGF-1) for the treatment of coronary artery disease. Clinical research in therapeutic angiogenesis is ongoing for a variety of atherosclerotic diseases, like coronary heart disease, peripheral arterial disease, wound healing disorders, etc.

Also, regarding the mechanism of action, pro-angiogenic methods can be differentiated into three main categories: gene-therapy, targeting genes of interest for amplification or inhibition; protein-therapy, which primarily manipulates angiogenic growth factors like FGF-1 or vascular endothelial growth factor, VEGF; and cell-based therapies, which involve the implantation of specific cell types.

There are still serious, unsolved problems related to gene therapy. Difficulties include effective integration of the therapeutic genes into the genome of target cells, reducing the risk of an undesired immune response, potential toxicity, immunogenicity, inflammatory responses, and oncogenesis related to the viral vectors used in implanting genes and the sheer complexity of the genetic basis of angiogenesis. The most commonly occurring disorders in humans, such as heart disease, high blood pressure, diabetes and Alzheimer's disease, are most likely caused by the combined effects of variations in many genes, and, thus, injecting a single gene may not be significantly beneficial in such diseases.

In contrast, pro-angiogenic protein therapy uses well-defined, precisely structured proteins, with previously defined optimal doses of the individual protein for disease states, and with well-known biological effects. On the other hand, an obstacle of protein therapy is the mode of delivery. Oral, intravenous, intra-arterial, or intramuscular routes of protein administration are not always as effective, as the therapeutic protein may be metabolized or cleared before it can enter the target tissue. Cell-based pro-angiogenic therapies are still early stages of research, with many open questions regarding best cell types and dosages to use.

Tumor angiogenesis

Without angiogenesis a tumor cannot grow beyond a limited size

Cancer cells are cells that have lost their ability to divide in a controlled fashion. A tumor consists of a population of rapidly dividing and growing cancer cells that progressively accrues mutations. However, tumors need a dedicated blood supply to provide the oxygen and other essential nutrients they require in order to grow beyond a certain size (generally 1–2 mm³).

Tumors induce blood vessel growth (angiogenesis) by secreting various growth factors (e.g. VEGF). Growth factors such as bFGF and VEGF can induce capillary growth into the tumor, which some researchers suspect supply required nutrients, allowing for tumor expansion. Unlike normal blood vessels, tumor blood vessels are dilated with an irregular shape. In 2007, it was discovered that cancerous cells stop producing the anti-VEGF enzyme PKG. In normal cells (but not in cancerous ones), PKG apparently limits beta-catenin, which solicits angiogenesis. Other clinicians believe angiogenesis really serves as a waste pathway, taking away the biological end products secreted by rapidly dividing cancer cells. In either case, angiogenesis is a necessary and required step for transition from a small harmless cluster of cells, often said to be about the size of the metal ball at the end of a ball-point pen, to a large tumor. Angiogenesis is also required for the spread of a tumor, or metastasis. Single cancer cells can break away from an established solid tumor, enter the blood vessel, and be carried to a distant site, where they can implant and begin the growth of a secondary tumor. Evidence now suggests the blood vessel in a given solid tumor may, in fact, be mosaic vessels, composed of endothelial cells and tumor cells. This mosaicity allows for substantial shedding of tumor cells into the vasculature, possibly contributing to the appearance of circulating tumor cells in the peripheral blood of patients with malignancies. The subsequent growth of such metastases will also require a supply of nutrients and oxygen and a waste disposal pathway.

Endothelial cells have long been considered genetically more stable than cancer cells. This genomic stability confers an advantage to targeting endothelial cells using antiangiogenic therapy, compared to chemotherapy directed at cancer cells, which rapidly mutate and acquire 'drug resistance' to treatment. For this reason, endothelial cells are thought to be an ideal target for therapies directed against them. Recent studies by Klagsbrun, et al. have shown, however, that endothelial cells growing within tumors do carry genetic abnormalities. Thus, tumor vessels have the theoretical potential for developing acquired resistance to drugs. This is a new area of angiogenesis research being actively pursued.

Two independent studies published in the journal Nature in 2010 November confirmed the ability of tumors to make their own blood vessels. When one group found that tumor stem cells could make their own blood vessels and avastin could not inhibit their early differentiation, the other group showed that selective targeting of endothelial cells generated by tumor-derived stem cells in mouse xenografts resulted in tumour reduction. These studies done in glioblastoma model may have implications in other tumors.

Formation of tumor blood vessels

Angiogenesis research is a cutting-edge field in cancer research, and recent evidence also suggests traditional therapies, such as radiation therapy, may actually work in part by targeting the genomically stable endothelial cell compartment, rather than the genomically unstable tumor cell compartment. New blood vessel formation is a relatively fragile process, subject to disruptive interference at several levels. In short, the therapy is the selection agent which is being used to kill a cell compartment. Tumor cells evolve resistance rapidly due to rapid generation time (days) and genomic instability (variation), whereas endothelial cells are a good target because of a long generation time (months) and genomic stability (low variation).

This is an example of selection in action at the cellular level, using a selection pressure to target and differentiate between varying populations of cells. The end result is the extinction of one species or population of cells (endothelial cells), followed by the collapse of the ecosystem (the tumor) due either to nutrient deprivation or self-pollution from the destruction of necessary waste pathways.

Angiogenesis-based tumor therapy relies on natural and synthetic angiogenesis inhibitors like angiostatin, endostatin and tumstatin. These are proteins that mainly originate as specific fragments of pre-existing structural proteins like collagen or plasminogen.

Recently, the first FDA-approved therapy targeted at angiogenesis in cancer came on the market in the US. This is a monoclonal antibody directed against an isoform of VEGF. The commercial name of this antibody is Avastin, and the therapy has been approved for use in colorectal cancer in combination with established chemotherapy.

Angiogenesis for cardiovascular disease

Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. It is a potent, physiological process that underlies the natural manner in which our bodies respond to a diminution of blood supply to vital organs, namely the production of new collateral vessels to overcome the ischemic insult. A large number of preclinical studies have been performed with protein-, gene- and cell-based therapies in animal models of cardiac ischemia, as well as models of peripheral artery disease. Reproducible and credible successes in these early animal studies led to high enthusiasm that this new therapeutic approach could be rapidly translated to a clinical benefit for millions of patients in the Western world suffering from these disorders. A decade of clinical testing both gene- and protein-based therapies designed to stimulate angiogenesis in underperfused tissues and organs, however, has led from one disappointment to another. Although all of these preclinical readouts, which offered great promise for the transition of angiogenesis therapy from animals to humans, were in one fashion or another, incorporated into early stage clinical trials, the FDA has, to date (2007), insisted that the primary endpoint for approval of an angiogenic agent must be an improvement in exercise performance of treated patients.

If one reviews in detail the various published angiogenesis clinical trials, it can be realized that most of these trials had success in achieving various secondary or supportive endpoints, but failed when attempting to demonstrate a statistically significant improvement in exercise performance, typically done by a treadmill exercise test. Perhaps the greatest reason for these trials' failure to achieve success is the high occurrence of the "placebo effect" in studies employing treadmill exercise test readout. Thus, even though a majority of the treated patients in these trials experience relief of such clinical symptoms as chest pain (angina), and generally performed better on most efficacy readouts, there were enough "responders" in the blinded placebo groups to render the trial inconclusive. In addition to the placebo effect, more recent animal studies have also highlighted various factors that may inhibit an angiogenesis response, including certain drugs, smoking, and hypercholesterolemia.

Although shown to be relatively safe therapies, no angiogenic therapeutic has yet made it through the gauntlet of clinical testing required for drug approval. By capitalizing on the large database of what did and did not work in previous clinical trials, results from more recent studies with redesigned clinical protocols give renewed hope that angiogenesis therapy will be a treatment choice for sufferers of cardiovascular disease resulting from occluded and/or stenotic vessels.

Early clinical studies with protein-based therapeutics largely focused on the intravenous or intracoronary administration of a particular growth factor to stimulate angiogenesis in the affected tissue or organ. Most of these trials did not achieve statistically significant improvements in their clinical endpoints. This ultimately led to an abandonment of this approach and a widespread belief in the field that protein therapy, especially with a single agent, was not a viable option to treat ischemic cardiovascular disease. However, the failure of gene- or cell-based therapy to deliver a suitable treatment choice for diseases resulting from poor blood flow has led to a resurgence of interest in returning to protein-based therapy to stimulate angiogenesis.

These failures suggested that either these are the wrong molecular targets to induce neovascularization, that they can only be effectively used if formulated and administered correctly, or that their presentation in the context of the overall cellular microenvironment may play a vital role in their utility. It may be necessary to present these proteins in a way that mimics natural signaling events, including the concentration, spatial and temporal profiles, and their simultaneous or sequential presentation with other appropriate factors.

Lessons learned from earlier protein-based studies, which indicated that intravenous or intracoronary delivery of the protein was not efficacious, have led to completed and ongoing clinical trials in which the angiogenic protein is injected directly into the beating ischemic heart.

Such localized administration of the potent angiogenic growth factor, human FGF-1, has recently given promising results in clinical trials in no-option heart patients. Angiogenesis was documented by angiographically visible "blushing", and functional exercise tests were also performed on a subset of patients. The attractiveness of protein therapy is that large amounts of the therapeutic agent can be injected into the ischemic area of interest, to pharmacologically start the process of blood vessel growth and collateral arteries formation. In addition, from pharmacokinetic data collected from the recent FGF-1 studies in the human heart, it appears that FGF-1, once it exits the heart, is cleared in less than three hours from the circulation. This would presumably prevent FGF-1 from stimulating unwanted angiogenesis in other tissues of the bodies where it could potentially cause harm, such as the retina and in the kidneys. No serious adverse events have yet to be noted in any of the completed or ongoing clinical trials in which the FGF-1 protein is used as the therapeutic agent to stimulate angiogenesis.

Left: Angiographic "blushing" following FGF-1 injection into the human heart. Right, measurements of pixel density in angiograms ("gray-value-analysis") indicating a threefold increase in vessel density in the treated human myocardium (3 months and 3 years).

Improvement in myocardial perfusion (blood supply) after FGF-1 treatment as demonstrated by single photon emission computed tomography (SPECT) imaging.

Another approach for stimulation angiogenesis in the heart is using FGF gene (instead of the protein) delivered by adenoviral vectors (e.g. Ad5FGF-4, Generx) during intracoronary infusion. Several clinical trials with angiogenic gene therapy have been completed with promising efficacy and safety data (e.g. AGENT trials). These trials tested intracoronary administration of Ad5FGF-4 in over 450 patients and demonstrated the safety of the product and the procedure. It is notable that when exercise tolerance was used as the primary end-point, the product did not achieve statistically significant effect primarily due to high placebo effect in the control groups. In contrast, when the more objective end-point of SPECT (measuring the extent of reversible myocardial ischemia) was used in the AGENT-2 clinical study, intracoronary administration of Ad5FGF4 resulted in a statistically significant therapeutic effect. Currently ongoing pivotal (Phase 3) clinical studies use myocardial perfusion (as measured by SPECT) as the primary end point.

Exercise

Angiogenesis is generally associated with aerobic exercise and endurance exercise. While arteriogenesis produces network changes that allow for a large increase in the amount of total flow in a network, angiogenesis causes changes that allow for greater nutrient delivery over a long period of time. Capillaries are designed to provide maximum nutrient delivery efficiency, so an increase in the number of capillaries allows the network to deliver more nutrients in the same amount of time. A greater number of capillaries also allows for greater oxygen exchange in the network. This is vitally important to endurance training, because it allows a person to continue training for an extended period of time. However, no experimental evidence suggests that increased capillarity is required in endurance exercise to increase the maximum oxygen delivery.

Macular degeneration

Overexpression of VEGF causes increased permeability in blood vessels in addition to stimulating angiogenesis. In wet macular degeneration, VEGF causes proliferation of capillaries into the retina. Since the increase in angiogenesis also causes edema, blood and other retinal fluids leak into the retina, causing loss of vision. Anti-angiogenic drugs targeting the VEGF pathways are now used successfully to treat this type of macular degeneration

Quantification

Quantifying vasculature parameters such as microvascular density has various complications due to preferential staining or limited representation of tissues by histological sections. Recent research has shown complete 3D reconstruction of tumor vascular structure and quantification of vessel structures in whole tumors in animal models. This has been applied to assessing effects of chemotherapeutic drugs.

Aortic ring assay

Matrigel tube formation assay

See also

• Aerobic exercise
• Arteriogenesis
• Proteases in angiogenesis

References

External links

• Attacking Tumor Vasculature, A cure for Cancer. PMAP The Proteolysis Map-animation
• Angiogenesis for Heart Disease from Angioplasty.Org
• What You Need to Get Started Researching Your Options from CancerGuide
• Angiogenesis - The Virtual Library of Biochemistry and Cell Biology
• Visualizing Angiogenesis with GFP
• NCI Understanding Cancer series on Angiogenesis
• TherapeuticAngiogenesis.com
• Angiogenesis Foundation
• "Anti-fungal drug stops blood vessel growth". EurekAlert. 2007-04-27. 
• Iris Pharma : animal models of Ocular Angiogenesis / Neovascularization
• Image analysis of angiogenesis with digital pathology
• William Li: Can we eat to starve cancer?
• Tumors Beware, Part 2 (from Beaker Blog)
• Angiogenesis - Thomas H. Adair and Jean-Pierre Montani. A textbook on the topic freely available at NCBI.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 血管新生阻害剤の概要 overview of angiogenesis inhibitors
• 2. 難治性狭心症マネージメントのための血管新生療法 therapeutic angiogenesis for management of refractory angina
• 3. 上皮性卵巣癌、卵管癌、 または腹膜癌における血管新生阻害剤の作用 the role of angiogenesis inhibitors in epithelial carcinoma of the ovary fallopian tube or peritoneum
• 4. 下肢末梢動脈疾患の症状を治療するための試験的治療 investigational therapies for treating symptoms of lower extremity peripheral artery disease
• 5. 糖尿病性網膜症：分類および臨床的特徴 diabetic retinopathy classification and clinical features

English Journal

• Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.

• Erös de Bethlenfalva-Hora C, Mertens JC, Piguet AC, Kettenbach J, Schmitt J, Terracciano L, Weimann R, Dufour JF, Geier A.Source*Hepatology, Department of Clinical Research, University of Bern, Bern, Switzerland.
• Clinical science (London, England : 1979).Clin Sci (Lond).2014 Feb 1;126(3):243-52. doi: 10.1042/CS20130089.
• RFA (radiofrequency ablation) is an established therapy for HCC (hepatocellular carcinoma). The multikinase inhibitor sorafenib prolongs survival in advanced HCC. We examined the effects of RFA alone and in combination with sorafenib on a bystanding tumour in a two-tumour rat model of HCC. A total o
• PMID 23822114

• 15-LO/15-HETE Mediated Vascular Adventitia Fibrosis via p38 MAPK-Dependent TGF-β.

• Zhang L, Li Y, Chen M, Su X, Yi D, Lu P, Zhu D.SourceDepartment of Pharmacology, Harbin Medical University-Daqing, Daqing, Heilongjiang Province, People's Republic of China.
• Journal of cellular physiology.J Cell Physiol.2014 Feb;229(2):245-57. doi: 10.1002/jcp.24443.
• 15-Lipoxygenase/15-hydroxyeicosatetraenoic acid (15-LO/15-HETE) is known to modulate pulmonary vascular medial hypertrophy and intimal endothelial cells migration and angiogenesis after hypoxia. However, it is unclear whether 15-HETE affects the adventitia of the pulmonary arterial wall. We performe
• PMID 23982954

• RECK Inhibits Stemness Gene Expression and Tumorigenicity of Gastric Cancer Cells by Suppressing ADAM-Mediated Notch1 Activation.

• Hong KJ, Wu DC, Cheng KH, Chen LT, Hung WC.SourceInstitute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan, Republic of China.
• Journal of cellular physiology.J Cell Physiol.2014 Feb;229(2):191-201. doi: 10.1002/jcp.24434.
• The Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) gene encodes a membrane-anchored glycoprotein that exhibits strong inhibitory activity against various matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase 10 (ADAM10). RECK functions as a tumor suppressor by i
• PMID 23881612

Japanese Journal

• 研究室紹介 海洋生物からの新しい医薬シーズの探索

• 小林 資正
• 生産と技術 66(1), 42-45, 2014
• NAID 40019942105

• Partial Discharge Characteristics for Small Gap of Electrode/Epoxy Interface in SF6 Gas

• Kono Yusuke,Kawakami Shigeru,Higuchi Yuriko [他],Endo F.,Okubo H.
• Biological and Pharmaceutical Bulletin, 137-144, 2014
• … Tumor-associated macrophages (TAMs) have an alternatively activated macrophage phenotype (M2) and promote cancer cell proliferation, angiogenesis and metastasis. …
• NAID 130003382116

• Cytochalasin H, an Active Anti-Angiogenic Constituent of the Ethanol Extract of Gleditsia sinensis Thorns

• Lee Jun,Yi Jin-Mu,Kim Haejin [他],Lee You Jin,Park Jong-Shik,Bang Ok-Sun,Kim No Soo
• Biological and Pharmaceutical Bulletin, 6-12, 2014
• … Angiogenesis, the process of new vessel formation from the pre-existing blood vasculature, is critical for continuous tumor growth and is considered to be a validated antitumor target. …
• NAID 130003382111

Related Links

• Angiogenesisとは - goo Wikipedia (ウィキペディア)

Angiogenesis inhibitor can be endogenous or come from outside as drug or a dietary component. Application in medicine [edit] Angiogenesis as a therapeutic target [edit] Angiogenesis may be a target for combating diseases ...

• Angiogenesis - definition of angiogenesis by Medical dictionary

angiogenesis [an″je-o-jen´ĕ-sis] 1. development of blood vessels in the embryo. 2. any formation of new blood vessels; see also neovascularization (def. 2) and revascularization. Called also angiopoiesis and vasculogenesis. adj., adj angiogenic.

Related Pictures

---

★リンクテーブル★

リンク元	「血管新生阻害薬」「angiogenic」「血管新生」「vascularization」「angiogenetic」
拡張検索	「therapeutic angiogenesis」「angiogenesis inducing agent」「angiogenesis factor」「angiogenesis modulating agent」

「血管新生阻害薬」

　　[★]

英

angiogenic inhibitor、anti-angiogenic agent

関

血管新生阻害剤、血管新生抑制因子、血管新生抑制剤、血管新生抑制物質、血管新生抑制薬、抗血管新生薬

血管内皮増殖因子 VEGF

[show details]

血管新生阻害剤 angiogenesis : 約 77 件
血管新生阻害薬 angiogenesis : 約 83 件

薬理学

• 抗VEGF抗体

• bevacizumab

• VEGF阻害薬

• sunitinib(SU11248) 受容体キナーゼ阻害薬 -> VEGFR-1, VEGFR-2, PDGFRを阻害
• sorafenib -> B-RAF, VEGFR-1, VEGFR-2, PDGFRを阻害
• vatalanib(PTK-787)

• サリドマイドとレナリドマイド

• thalidomide
• lenalidomide

「angiogenic」

　　[★]

• 血管新生の、血管形成の、血行性の、血管原性の

関

angiogenesis、angiogenetic、angioneogenesis、angioplasty、haematogenous、hematogenic、hematogenous、hematogenously、neoangiogenesis、neovascularisation、neovascularization、vascularization、vasculogenesis、vasculogenic、vasogenic

「血管新生」

　　[★]

英

angiogenesis

同

二次血管発生

関

脈管形成 vasculogenesis

• 既存の血管から芽が出て新たな血管が形成される

==血管新生促進

• bFGF FGF-2
• VEGF

血管新生抑制

• angiostatin
• endostatin
• vasculostatin

「vascularization」

　　[★]

• 血管新生、血管新生反応、血管新生化

関

angiogenesis、angiogenetic、angiogenic、angioneogenesis、neoangiogenesis、neovascularisation、neovascularization、vascularize

　

「angiogenetic」

　　[★]

• 血管形成誘導の、血管新生の

関

angiogenesis、angiogenic、angioneogenesis、neoangiogenesis、neovascularisation、neovascularization、vascularization

「therapeutic angiogenesis」

　　[★]

• 治療的血管新生、治療的血管新生療法、血管新生療法、血管新生促進療法

関

angiogenic therapy

「angiogenesis inducing agent」

　　[★]

• 血管新生促進薬、血管新生促進剤

関

angiogenesis factor、angiogenic factor

「angiogenesis factor」

　　[★]

• 血管形成因子

関

angiogenesis inducing agent、angiogenic factor

「angiogenesis modulating agent」

　　[★]

• 血管新生調節薬、血管新生調節剤